Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 11/20 | 0.47 |
| ▸ | CTSS | P25774 | 7/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372203 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL74360 | 1.00 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| Alanine SCHEMBL9582963 | 0.92 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4766284 | 0.87 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25270811 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5198000 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27426180 | 0.85 | CYP2D6 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17616112 | 0.85 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8972253 | 0.85 | CYP2D6 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL28740911 | 0.84 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876507-A | Trisubstituted olefin tertiary phosphine compound and preparation method thereof | 湖北大学 | 2021-06-01 | — | — | CN | claimed |
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4655292-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | Ab2 Therapeutics, S. L. (ES) | 2025-12-03 | — | — | EP | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4126861-B1 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BAYER AG (DE) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-0355331-A2 | Poly(aminoalkyl)aminocarbonyl aminoacyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-02-28 | — | — | EP | disclosed |
| US-4902706-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents | G. D. SEARLE & CO. (US) | 1990-02-20 | — | — | US | disclosed |
| US-4900746-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-02-13 | — | — | US | disclosed |
| WO-1990000052-A1 | POLY(AMINOALKYL)AMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0349921-A2 | Etheral n-terminal aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| US-4877785-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0310072-A2 | Non-peptidyl beta-succinamidoacyl aminodiols as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CA1 2824/4885CA2 1024/4885CA7 1184/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | CA1 3464/4885CA2 4634/4885CA7 3747/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CA1 3464/4885CA2 4634/4885CA7 3747/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CA1 3568/4885CA2 2848/4885CA7 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.